MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06483048 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Fallopian Tube Carcinosarcoma
Recurrent Female Reproductive System Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Ovarian Carcinosarcoma
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Primary Peritoneal Carcinosarcoma
Refractory Fallopian Tube Carcinoma
Refractory Female Reproductive System Carcinoma
Refractory Ovarian Carcinoma
Refractory Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Autologous MUC1-activated T-cells
DRUG: Bendamustine
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
PROCEDURE: Echocardiography
PROCEDURE: Leukapheresis
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Multigated Acquisition Scan
PROCEDURE: Positron Emission Tomography

Sponsor

Mayo Clinic